Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Veracyte, Inc. - Common Stock (NQ:VCYT)

43.77 -1.34 (-2.96%)
Streaming Delayed Price Updated: 1:37 PM EST, Jan 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 194,360
Open 44.52
Bid (Size) 43.74 (1,800)
Ask (Size) 43.79 (300)
Prev. Close 45.11
Today's Range 43.59 - 45.03
52wk Range 22.61 - 50.71
Shares Outstanding 67,473,870
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Veracyte to Participate in the 44th Annual J.P. Morgan Healthcare Conference
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte Inc (NASDAQ:VCYT) Emerges as a Top Affordable Growth Stock ↗
Veracyte (VCYT) exemplifies the GARP strategy, offering strong growth, a reasonable industry price, and a solid debt-free financial foundation. 
Via Chartmill

Performance

YTD
+3.3%
+3.3%
1 Month
-1.3%
-1.3%
3 Month
+24.7%
+24.7%
6 Month
+61.6%
+61.6%
1 Year
+3.0%
+3.0%

More News

Read More
News headline image
Veracyte Inc (NASDAQ:VCYT): A GARP Stock With Strong Growth and a Reasonable Price ↗
Via Chartmill
News headline image
Veracyte to Participate in Upcoming Investor Conferences
From Veracyte, Inc.
Via Business Wire
News headline image
Earnings Scheduled For November 4, 2025 ↗
Via Benzinga
News headline image
Earnings Scheduled For August 6, 2025 ↗
Via Benzinga
News headline image
Johnson Controls, Babcock & Wilcox, Lemonade, Lumentum, Teva Pharmaceutical And Other Big Stocks Moving Higher On Wednesday ↗
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
Via Benzinga
News headline image
Veracyte Announces Third Quarter 2025 Financial Results
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte Announces First Publications Using Afirma GRID Research Tool To Help Usher in Next Generation of Thyroid Nodule Testing
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte Inc (NASDAQ:VCYT): An Affordable Growth Candidate in Biotech ↗
Via Chartmill
News headline image
Veracyte to Release Third Quarter 2025 Financial Results on November 4, 2025
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte Inc (NASDAQ:VCYT) Presents a Strong Growth and Breakout Opportunity ↗
Via Chartmill
News headline image
Veracyte Inc (NASDAQ:VCYT): An Affordable Growth Candidate in Cancer Diagnostics ↗
Via Chartmill
News headline image
Veracyte Announces that Decipher-Enabled Biomarker Predicts Hormone Therapy Benefit in Men with Recurrent Prostate Cancer
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte Announces First Prospective Validation Data for Biomarker Predicting Hormone Therapy Benefit in Men with Recurrent Prostate Cancer Will Be Presented at ASTRO 2025
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte Announces That More Than 10 Afirma-Focused Studies Will Be Presented at the 2025 American Thyroid Association Annual Meeting
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte Completes NIGHTINGALE Clinical Utility Trial Enrollment for Percepta Nasal Swab Lung Cancer Test
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte Announces New Study Published in Cell Shows that Decipher Prostate Test Predicts Chemotherapy Benefit in Patients with Metastatic Prostate Cancer
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte Inc (NASDAQ:VCYT) Emerges as a Strong Value Pick with Solid Fundamentals and Growth Potential ↗
Via Chartmill
News headline image
Veracyte (VCYT) Q2 Revenue Jumps 14% ↗
Via The Motley Fool
News headline image
Veracyte Announces Second Quarter 2025 Financial Results
From Veracyte, Inc.
Via Business Wire
News headline image
Cathie Wood's Ark Invest Loads Up On Absci, Offloads CRISPR Therapeutics ↗
Via Benzinga
News headline image
VERACYTE INC (NASDAQ:VCYT) – An Undervalued Stock with Strong Fundamentals ↗
Via Chartmill

Frequently Asked Questions

Is Veracyte, Inc. - Common Stock publicly traded?
Yes, Veracyte, Inc. - Common Stock is publicly traded.
What exchange does Veracyte, Inc. - Common Stock trade on?
Veracyte, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Veracyte, Inc. - Common Stock?
The ticker symbol for Veracyte, Inc. - Common Stock is VCYT on the Nasdaq Stock Market
What is the current price of Veracyte, Inc. - Common Stock?
The current price of Veracyte, Inc. - Common Stock is 43.77
When was Veracyte, Inc. - Common Stock last traded?
The last trade of Veracyte, Inc. - Common Stock was at 01/08/26 01:37 PM ET
What is the market capitalization of Veracyte, Inc. - Common Stock?
The market capitalization of Veracyte, Inc. - Common Stock is 2.95B
How many shares of Veracyte, Inc. - Common Stock are outstanding?
Veracyte, Inc. - Common Stock has 3B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.